Clinical Trials Logo

Abortion, Habitual clinical trials

View clinical trials related to Abortion, Habitual.

Filter by:

NCT ID: NCT03905395 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Meditation and Mindfulness for Recurrent Pregnancy Loss

Start date: February 2, 2019
Phase: N/A
Study type: Interventional

In the Danish Recurrent Pregnancy Loss Unit in Rigshospitalet in Copenhagen recurrent pregnancy loss (RPL) is defined as three og more consecutive pregnancy losses in accordance with current European guidelines. RPL affects approximately 3% of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no effective treatment to improve the chance of a live birth. 42% of the women referred to RPL Unit in Rigshospitalet has a high stress level where as it's 22% in the background population trying to achieve parenthood. It's also known that 8,8 % of RPL patients have a depression at referral where as it's 2,2 % in the background population trying to achieve parenthood. The study is a RCT including 62 patients - 31 in each arm. One arm will be taught in meditation and mindfulness three courses over a 7 week period. This group will also do meditation every day for 7 weeks. The other arm will have no intervention. This study will investigate if a 7 weeks course in meditation and mindfulness is a useful tool to reduce stress and the psychological consequences for women and their partner treated in RPL Unit in Rigshospitalet, Copenhagen. Furthermore this study will investigate if there's a marital benefit such as reinforcement in their relationsship from practicing meditation and mindfulness. There is no previous study that has investigated meditation and mindfulness for RPL. This study has the potential to establish mental health support as a supplement to the medical and clinical treatment for RPL patients.

NCT ID: NCT03902912 Recruiting - Clinical trials for Recurrent Miscarriage

Effect of Prednisolone Treatment on Uterine Natural Killer Cells

Start date: July 30, 2019
Phase: Phase 3
Study type: Interventional

This study aims to investigate the role of uNK cells and the association with prednisolone.

NCT ID: NCT03671174 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Immunosuppressant Regimens for Living Fetuses Study

Start date: August 2, 2019
Phase: N/A
Study type: Interventional

Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based on the tendency to thrombosis formation and placental inflammation in the pathogenesis of UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss patients with UCTD.

NCT ID: NCT03577314 Recruiting - Oral Health Clinical Trials

Is There an Interaction Between Recurrent Miscarriage and Dental Health

Start date: April 15, 2018
Phase:
Study type: Observational

Oral infections can trigger the production of pro-inflammatory mediators that may be risk factors for miscarriage. The investigators investigated whether oral health care patterns that may promote or alleviate oral inflammation were associated with the history of miscarriage in Turkish women.

NCT ID: NCT03305263 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

Start date: January 25, 2018
Phase: Phase 3
Study type: Interventional

Recurrent pregnancy loss (RPL) defined as 3 or more pregnancy losses affects approximately 3% of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no effective treatment to improve the chance of a live birth. Exciting indications for using Hydroxychloroquine (HCQ) include: Malaria profylaxis and treatment, systemic and discoid lupus erythematosus (SLE) and rheumatoid athritis (RA). HCQ has been reported to have the following properties (anti-thrombotic, vascular-protective, immunomodulatory, improving glucose tolerance, lipid-lowering, and anti-infectious). There is no data concerning the benefit of HCQ in RPL. Administration for other indications provides extensive safety data during pregnancy. This study has the potential to establish support for a new treatment option for unexplained RPL.

NCT ID: NCT03214185 Recruiting - Infertility, Female Clinical Trials

Effects of PGS2.0 in Patients With Unexplained RPL

Start date: February 6, 2018
Phase: N/A
Study type: Interventional

50%-60% of the known causes of recurrent pregnancy loss(RPL) are associated with embryonic aneuploidy, such that preimplantation genetic screening (PGS) on embryos acquired by assisted reproductive treatment should improve the rate of pregnancy and live birth in those patients. In dispute though the clinical application of PGS has been, a series of studies show that the new generation of PGS(PGS 2.0), based on blastocyst biopsy followed by whole genome analysis, has significantly improved the clinical outcome of IVF treatment. At present, there is still a need for the evidence of the use of PGS 2.0 in RPL patients, who may benefit from this emerging technology considering the prevalence of genetic abnormalities and the number of transferable embryos in this population. An earlier single center RCT conducted by our IVF center displayed higher implantation rate, clinical pregnancy rate and ongoing pregnancy rate calculated by per embryo transfer(ET) cycle in IVF/ICSI+PGS group compared with IVF/ICSI group. This multi-center prospective randomized clinical trial is to provide more data to determine whether the clinical outcomes are significantly improved per treatment cycle such that provide evidence for the application of PGS in RPL patients. Besides, risk factors of PGS outcome are to be analyzed from multi-center data to build a model for prediction of the possible outcomes of PGS and direction of the clinical choice.

NCT ID: NCT03009370 Recruiting - Ovarian Reserve Clinical Trials

The Effect of the Ovarian Reserve on the Recurrent Pregnancy Loss

Start date: July 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether ovarian reserve is related to recurrent pregnancy loss

NCT ID: NCT02633475 Recruiting - Clinical trials for Abortion, Spontaneous

Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk

Start date: August 2015
Phase: N/A
Study type: Observational

This study aimed to assess the correlation between the interleukin-10 (IL-10)-1082A/G polymorphism and idiopathic recurrent miscarriage (IRM) of Chinese Han. A total of 100 women with IRM and 100 control women with a successful pregnancy will be included in this study. Then genotyping will be performed.

NCT ID: NCT02303171 Recruiting - Clinical trials for Antiphospholipid Syndrome

Use of Warfarin After the First Trimester in Pregnant Women With APS

Start date: November 2014
Phase: Phase 4
Study type: Interventional

Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)

NCT ID: NCT02144064 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin

Start date: June 23, 2019
Phase: Phase 3
Study type: Interventional

Objective To determine maternal and fetal outcomes in women with Unexplained RPL managed with aspirin or unfractionated heparin (UFH) plus aspirin during pregnancy. Design: prospective clinical controlled study. Setting: high-risk pregnancy unit- Benha university hospital. Methods: Pregnant women with unexplained recurrent miscarriage attending high-risk pregnancy unit. 200 selected patients with previous unexplained recurrent miscarriage are divided into 2 groups: group A (n = 100) receive low-dose aspirin (81 mg once daily orally) plus heparin (5000 IU) every 12 h with the first positive pregnancy test while group B (n = 100) receive no thing . Main outcome measures: Maternal outcomes included thromboembolic and haemorrhagic complications and pregnancy-induced hypertension .Prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications